AstraZeneca Pharma India Limited: history, ownership, mission, how it works & makes money

A Brief History of AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited, a subsidiary of AstraZeneca plc, was established in 1979 as Astra India. It evolved into a significant player in the Indian pharmaceutical market, focusing on innovative medicines across multiple therapeutic areas. In 1996, the company adopted its current name, AstraZeneca Pharma India Limited, reflecting its integration within the global AstraZeneca structure.

In 2000, AstraZeneca acquired the Indian pharmaceutical company, Zeneca, which marked a strategic enhancement of its portfolio in India. AstraZeneca Pharma India Limited has since made significant investments in research and development, continually expanding its product offerings. By 2021, the company reported a total revenue of ₹1,720 crores, indicating growth driven by both domestic operations and exports.

Financial Performance

AstraZeneca Pharma India Limited has demonstrated solid financial performance over the years. Below is a

In 2021, AstraZeneca Pharma India launched significant products including a new cancer treatment and a COVID-19 vaccine, which contributed to revenue spikes. The company consistently reinvests profits into R&D, which accounted for approximately 12% of total revenue in 2021.

Market Position and Research Initiatives

The company has established itself as a leader in multiple therapeutic segments such as oncology, respiratory diseases, cardiovascular health, and diabetes care. AstraZeneca’s market share in the Indian pharmaceutical sector was around 3.1% as of 2022.

AstraZeneca Pharma India Limited operates several research facilities across the country, focusing on innovative drug discovery and development. Over the years, this commitment has resulted in over 20 NDA (New Drug Applications) approved by the Indian regulatory authorities.

AstraZeneca's strategic collaborations with local entities and research institutions have been pivotal. For instance, in 2021, the company entered a partnership with a prominent Indian university to advance research in oncology.

In terms of workforce, AstraZeneca Pharma India Limited has approximately 2,500 employees as of 2022, highlighting its position as a substantial employer in the Indian biopharmaceutical sector.

Future Outlook

Looking ahead, AstraZeneca Pharma India Limited aims to expand its presence in the biopharmaceutical market, with plans to introduce over 10 new products in the next two years. The company is also investing in digital health initiatives, reflecting broader trends in the healthcare industry.

With a growing portfolio and ongoing R&D initiatives, the company is well-positioned to capture new market opportunities in India and beyond, driven by a commitment to innovative healthcare solutions.

A Who Owns AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca PLC, a global biopharmaceutical company headquartered in Cambridge, United Kingdom. As of the latest available data, AstraZeneca PLC holds a significant ownership stake in AstraZeneca Pharma India Limited.

As of April 2023, 75% of AstraZeneca Pharma India Limited's shares are owned by AstraZeneca PLC. The remaining shares are held by public shareholders and institutional investors.

The shareholding pattern for AstraZeneca Pharma India Limited is as follows:

AstraZeneca PLC's investment in AstraZeneca Pharma India Limited is part of its broader strategy to penetrate emerging markets. This aligns with their aim to increase revenue from high-growth regions, particularly in the pharmaceutical sectors.

Financially, AstraZeneca Pharma India Limited reported a revenue of approximately INR 1,342 crores for the fiscal year ended December 2022. This was up from INR 1,200 crores in the previous fiscal year, demonstrating a year-over-year growth of 11.83%.

The company's performance is also reflected in its market capitalization, which was approximately INR 16,500 crores as of October 2023. The stock performance has shown a steady increase, with a notable return of 18% over the last year. This increase aligns with the overall growth trajectory of the pharmaceutical industry in India, which is expected to reach USD 130 billion by 2030, as per various market reports.

Additionally, AstraZeneca Pharma India Limited is involved in various therapeutic areas, including oncology, cardiovascular, renal, respiratory, and other diseases. Its strategic initiatives and strong product pipeline contribute to its robust ownership structure led by AstraZeneca PLC.

As of the latest regulatory filings, AstraZeneca Pharma India Limited continues to focus on expanding its R&D capabilities, further enhancing its position in the competitive Indian pharmaceutical market.

AstraZeneca Pharma India Limited Mission Statement

AstraZeneca Pharma India Limited is dedicated to the mission of delivering life-changing medicines to patients across the globe. Their commitment focuses on scientific innovation, operational excellence, and addressing unmet medical needs. This mission is reflected in their strategic priorities and the values that guide their operations.

The company aims to improve access to treatment and healthcare through partnerships and initiatives that enhance health outcomes. AstraZeneca strives to maintain a patient-centric approach, ensuring that its research and development efforts align with the needs of patients and healthcare professionals.

As of October 2023, AstraZeneca Pharma India Limited reported robust operational performance, with revenues and investments directed toward expanding their therapeutic offerings. Below is a summary table of recent financial performance data.

AstraZeneca’s diverse portfolio underlines its mission. The company is engaged in various therapeutic areas, including oncology, cardiovascular, renal, and respiratory diseases. This diversification is critical to addressing a wide array of patient needs.

The company further emphasizes sustainability in its mission. AstraZeneca aims to reduce its environmental impact and improve health equity. For instance, they have committed to achieving net-zero carbon emissions by 2025 within their global operations.

In 2023, AstraZeneca Pharma India Limited's investments in innovation have increased, demonstrating their commitment to developing new therapies. Their strategic collaboration with local healthcare systems and research institutions allows them to gain insights into patient needs and market trends, resulting in the development of targeted therapies.

In summary, AstraZeneca Pharma India Limited operates with a mission that prioritizes patient needs, scientific advancement, and sustainability, reflecting its role as a key player in the pharmaceutical industry.

How AstraZeneca Pharma India Limited Works

AstraZeneca Pharma India Limited operates as a subsidiary of AstraZeneca plc, focusing on the development and commercialization of pharmaceutical products across various therapeutic areas. The company is based in Bangalore and has been active in India for over two decades. As of 2023, AstraZeneca Pharma India has a wide portfolio, including oncology, cardiovascular, respiratory, and diabetes medications.

In the financial year ending December 31, 2022, AstraZeneca Pharma India reported a total revenue of INR 3,534 crore, showcasing a growth of 8% compared to the previous year. The operating profit for the same period was approximately INR 1,053 crore, with a profit margin of around 30%.

The company invests significantly in research and development (R&D) to enhance its product pipeline. In 2022, AstraZeneca Pharma India allocated INR 400 crore towards R&D, focusing on innovative therapies and improving existing medications. This investment is part of a broader commitment to enhancing healthcare outcomes through science-driven solutions.

AstraZeneca Pharma India's market capitalization was approximately INR 24,000 crore as of October 2023. The stock has shown resilient performance, with a year-to-date increase of 15%. The stock trades on the National Stock Exchange of India (NSE) under the ticker symbol 'ASTRAZEN.' Over the past year, the stock reached a high of INR 4,400 and a low of INR 2,800.

AstraZeneca Pharma India collaborates with various healthcare professionals and institutions to promote its products. The company's marketing strategy includes engaging in educational programs and providing resources to healthcare providers to improve patient outcomes. The firm has established a strong distribution network, ensuring that its products reach various segments of the Indian market efficiently.

Moreover, AstraZeneca Pharma India adheres to the stringent regulatory requirements set by the Drug Controller General of India (DCGI). The company is committed to maintaining high standards of quality and safety throughout its manufacturing processes, resulting in the successful approval of multiple products in the last few years.

In terms of product offerings, AstraZeneca Pharma India has several key products, such as:

• Tagrisso (Osimertinib) - used in lung cancer treatment
• Farxiga (Dapagliflozin) - for diabetes management
• Symbicort (Budesonide/Formoterol) - for asthma and COPD
• Brilinta (Ticagrelor) - used for cardiovascular issues

The company maintains a robust corporate social responsibility (CSR) strategy, focusing on health improvement initiatives. In 2022, AstraZeneca Pharma India contributed approximately INR 30 crore towards various community health programs, emphasizing access to medicines and healthcare education.

By leveraging its global presence and local expertise, AstraZeneca Pharma India aims to enhance its market share while continuing to innovate in the pharmaceutical sector. The company's ongoing efforts to expand its product line and improve accessibility reflect its commitment to advancing healthcare in India.

How AstraZeneca Pharma India Limited Makes Money

AstraZeneca Pharma India Limited operates primarily through the development, manufacturing, and sale of pharmaceutical products. The company's revenue streams can be categorized into several key areas, including prescription medicines, research and development (R&D), and strategic collaborations.

Revenue Breakdown

In the financial year ending December 2022, AstraZeneca Pharma India reported a total revenue of ₹3,187.3 Crores. The breakdown of this revenue by segment is as follows:

Prescription Medicines as a Revenue Driver

Prescription medicines, particularly in the area of oncology, cardiovascular, and respiratory diseases, are the primary revenue drivers for AstraZeneca Pharma India. In FY 2022, the oncology segment alone contributed approximately ₹1,100 Crores, representing a growth of 15% from the previous year.

Research and Development Investment

AstraZeneca Pharma India allocates a significant portion of its budget to research and development. For the year ending December 2022, R&D expenditure was reported at ₹606 Crores, which accounts for 19% of the total revenue. This investment focuses on developing innovative therapies and enhancing existing product lines, thereby ensuring a robust pipeline of future revenue.

Strategic Collaborations

The company is also engaged in strategic collaborations with various healthcare organizations and government entities to enhance its market presence. In 2022, AstraZeneca Pharma India entered into a partnership with the Indian government for the supply of vaccines, generating an estimated revenue of ₹150 Crores during the fiscal year. This type of collaboration not only boosts sales but also enhances the company's reputation and credibility in the market.

Market Trends and Growth Potential

The Indian pharmaceutical market is projected to grow at a compound annual growth rate (CAGR) of approximately 11-12% from 2023 to 2027. Given AstraZeneca's strong foothold in oncology and diabetes care, the company is well-positioned to capitalize on this growth trend. Furthermore, the rising demand for specialty drugs presents additional opportunities for AstraZeneca Pharma India.

Financial Performance Indicators

AstraZeneca Pharma India's ability to generate substantial revenue is driven by its strategic focus on high-demand therapeutic areas, robust R&D investments, and effective partnerships. As the company continues to innovate and expand its product offerings, its revenue generation strategies remain integral to its long-term growth and sustainability in the competitive pharmaceutical landscape.